For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
To compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.
DiagnosisBreast cancer that has higher risk features (i.e. – positive lymph nodes and/or large size)
Patients must have undergone a lumpectomy or mastectomy.
Patients cannot have had any prior chemotherapy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Study agents: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin
- Lab Biomarker Analysis
- Quality of Life questionnaires
- ARM A: Doxorubicin + Cyclophosphamide x 4 cycles, followed by Paclitaxel
- ARM B: Doxorubicin + Cyclophosphamide x 4 cycles, followed by Paclitaxel + Carboplatin
After completion of study therapy, patients are followed for at least 10 years.
For more information, visit ClinicalTrials.gov